James Hardie Industries (JHX) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
11 Aug, 2026Executive summary
Net sales for Q1 reached $1.475 billion, up 64% year-over-year, driven by the AZEK acquisition and strong organic growth, exceeding guidance.
Adjusted EBITDA was $422 million (28.6% margin), up 79%, with synergy realization from AZEK integration ahead of schedule.
Free cash flow increased 145% to $254 million, supporting deleveraging and future growth.
Siding & Trim led segment gains with 20% organic growth; Europe and Australia/New Zealand delivered double-digit revenue growth.
Expanded partnerships and integration of AZEK and Hardie sales forces drove channel expansion and commercial synergies.
Financial highlights
Adjusted EPS was $0.36, up 13% year-over-year, diluted by increased share count from AZEK acquisition.
Free cash flow for the quarter was $254 million, driven by higher profitability and lower capex.
Adjusted EBITDA margin improved 230bps to 28.6%; operating income increased 57% to $218 million.
Net leverage reduced to 2.7x, targeting ≤2.0x by Q2 FY28.
Adjusted effective tax rate was 21.7%.
Outlook and guidance
Q2 FY27 net sales guidance: $1.485–$1.575 billion; Adjusted EBITDA: $420–$455 million.
Full-year FY27 sales outlook raised to $5.564–$5.723 billion (5.9%–9% pro forma growth); Adjusted EBITDA $1.536–$1.625 billion.
Free cash flow for FY27 expected to exceed $500 million; capex to be 6%–7% of net sales.
Guidance reflects prudent planning amid macro uncertainty.
Latest events from James Hardie Industries
- Board seeks approval for revised executive and director pay structures aligned with shareholder feedback.JHX
Proxy filing - Redesigned CEO equity grant and improved compensation structure headline annual meeting proposals.JHX
Proxy filing - Shareholders will vote on board, pay, auditor, and governance changes after a year of major transformation.JHX
Proxy filing - Director elections, say-on-pay, auditor ratification, and governance amendments up for vote.JHX
Proxy filing - Major acquisition, board refresh, and executive pay overhaul highlight FY26 governance and strategy.JHX
Proxy filing - AZEK acquisition and synergy gains drove strong sales and EBITDA growth, with FY27 targets raised.JHX
Q4 2026 - Net sales up 30% to $1.24B, with higher EBITDA and raised FY26 guidance amid synergy progress.JHX
Q3 2026 - Q2 FY26 sales jumped 34% on AZEK deal; margins fell, but FY26 outlook and synergies improved.JHX
Q2 2026 - Record Q1 EBITDA and 4% sales growth achieved; FY25 guidance reaffirmed amid market headwinds.JHX
Q1 2025